Bispecific antibodies are emerging as a novel therapeutic approach, which has potential to treat chronic diseases as well as to diagnose diseases efficiently with fewer side effects.
Global Bispecific Antibody Market Insight 2028 Report Highlights:
- Research Methodology
- Global and Regional Market Analysis
- Global Bispecific Antibody Market Opportunity Assessment: > USD 20 Billion
- Market Sales Insight 2020 Till 2028
- Approved Drug Sales Insight Till Dec 2021(Updated Every Quarter)
- Approved Drug Sales Forecast Till 2028
- Approved Drug In Market: 4 Drugs
- Approved Bispecific Antibody Drug Patent, Price and Sales insight 2020 Till 2028
- Future Market Assessment By Indication Till 2028
- Ongoing Clinical Trials Assessment by Status, Phase and Region
- Key Market Dynamics
- Competitor Landscape
Download Report:
Bispecific antibodies are emerging as a novel therapeutic approach, which has potential to treat chronic diseases as well as to diagnose diseases efficiently with fewer side effects. Bispecific antibodies due to combination of two binding specificities, improve the selectivity and efficacy of antibody-based treatment of human disease. They are designed to combine specificities of two antibodies and simultaneously involved in addressing different antigens or epitopes. Bispecific antibodies with ‘two-target’ functionality can interfere with multiple surface receptors or ligands associated, for example with cancer, proliferation or inflammatory processes. Till date, 4 bispecific antibodies have entered the global market.
Blincyto developed by Amgen is the first bispecific antibody approved for the management of MRD+ B Cell Precursor Acute Lymphocytic Leukemia (ALL) and relapsed or refractory B-cell Precursor ALL. In addition to this, Hemlibra is the recently approved Bispecific monoclonal antibody, which consists of Emicizumab-kxwh and used in the management of hemophilia and hemophilia with inhibitors. Currently, the global bispecific antibody market is concentrated with the robust sales of these two bispecific antibodies. Since the entrance of these drugs, the global sales of these drugs have seen constant rise. For instance, the sales of Blincyto increased 28% year-over-year for the fourth quarter, driven by volume growth, and 25% for the full year, driven by volume growth during 2021.
Apart from these two, Rybrevant developed by Janssen Pharmaceuticals has also gained approval by US FDA. However, the sales of the drug have not yet reported and are expected to be available in forthcoming years. More recently in 2022, Faricimab (Vabysmo, Roche) was approved by the US Food and Drug Administration to treat wet age-related macular degeneration (AMD) and diabetic macular edema (DME). It is the fourth bispecific antibody which has been granted approval till date. As per our analysis, these two bispecific antibodies are also expected to follow the similar pattern like Blincyto or Hemlibra, thus boosting the growth of market.
The great zeal of interest by pharmaceutical companies can be justified by the presence of robust clinical pipeline of drugs, which are expected to enter the market in next few years. Pharmaceutical companies involved in the development of bispecific antibodies strongly believe that their products are superior to first generation bispecifics. Moreover, their role has not only confined to oncological use but also the non-oncological use which rejection of organ transplants, inflammatory and autoimmune diseases, cardiovascular disease, infectious disease, allergies and other making their usage wide enough which will drive the market. However, it is expected that the oncological sector will dominate the market due to increase prevalence of cancer and large product approvals.
As per our report findings, the global bispecific antibody market is expected to surpass US$ 20 Billion by 2028. Sedentary lifestyle is one of the causes of people putting themselves at a higher risk of being prone to development of chronic diseases. Furthermore, people over the years have changed their food habits. The adoption of preservative driven food and fast-food has been complimenting the sedentary lifestyle adoption. This has put them at a higher risk of developing chronic diseases. Better cancer treatment is required as the number of chronic disease cases increase. This will have a positive impact on the growth of market. In addition to this, rising investments by pharmaceutical giants and large number of ongoing clinical trials will also drive the growth of market during the forecast period.
The global bispecific antibody report provides an overview of the market based on key parameters such as market size, estimated sales, and key drivers and challenges. The size of the market is expected to grow on a large scale during the forecast period (2021-2028). The research offers a detailed study on the ongoing clinical trials insight segment on the basis of phase, status, region, and by indication.
Contact:
Neeraj Chawla
Kuick Research
Research Head
+91-9810410366